Tizanidine Hydrochloride Capsule
Product Images NDC 68788-8747

Product Visual Gallery

This gallery contains 6 technical images submitted to the FDA as part of the official labeling for Tizanidine Hydrochloride (NDC 68788-8747). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Preferred Pharmaceuticals Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Tizanidine Structure (Fe05ad15 Db11 4d9e 9fb8 721cec4633d9 01)

Chemical structure of tizanidine hydrochloride showing a chlorinated indole ring fused with a thiazole ring and a pyrrolidine moiety attached, representing the molecular composition of the active pharmaceutical ingredient.*

FDA Label Image

Figure 1 (Fe05ad15 Db11 4d9e 9fb8 721cec4633d9 02)

A line graph depicting plasma concentration levels of tizanidine over time following dosing. The x-axis represents hours from dosing (0 to 26), while the y-axis shows plasma tizanidine concentration in ng/mL (0 to 6). The graph compares four conditions: 2 x 4 mg tizanidine tablets and capsules, each with and without food.*

FDA Label Image

Figure 2 (Fe05ad15 Db11 4d9e 9fb8 721cec4633d9 03)

A line chart depicting improvement in Ashworth Score over 6 hours post-dose for three groups: 16 mg tizanidine, 8 mg tizanidine, and placebo. The vertical axis shows improvement scores (negative values indicating greater improvement), and the horizontal axis shows time in hours post-dose. Data points include error bars.*

FDA Label Image

Figure 3 (Fe05ad15 Db11 4d9e 9fb8 721cec4633d9 04)

A line plot showing improvement in Ashworth Score over three time points: End of Titration (Week 3), End of Maintenance (Week 7), and Endpoint (Last Observation Carried Forward). Two groups are compared: tizanidine with mean dose 28.8 mg, and placebo. Data markers include squares for tizanidine and circles for placebo, with error bars indicating variability.*

FDA Label Image

Tizanidine Hydrochloride Capsules 4mg (Fe05ad15 Db11 4d9e 9fb8 721cec4633d9 06)

Label for Tizanidine Hydrochloride Capsules 4 mg, a human prescription drug by Preferred Pharmaceuticals Inc., Anaheim, CA. The label states each capsule contains 4.58 mg tizanidine hydrochloride USP equivalent to 4 mg tizanidine base. It includes storage instructions, manufacturer Ingenus Pharmaceuticals LLC, and warnings about drowsiness and child-resistant closure. Directions are provided in English and Spanish on a yellow background.*

FDA Label Image

Image (Fe05ad15 Db11 4d9e 9fb8 721cec4633d9 143 1)

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.